function magicapp(info){

  var rec = [ {
  "recommendationId" : 51119,
  "shortCode" : "jWoK8j",
  "guidelineId" : 3384,
  "sectionId" : 41933,
  "order" : 1,
  "strength" : "WEAK",
  "status" : "NOTSET",
  "heading" : "",
  "text" : "In women with a singleton pregnancy and history of preterm birth before week 37, without an obvious course such as uterine malformation or conization, the administration of progesterone, might be considered in order to reduce the risk of a repeated preterm birth before&nbsp;week 33-35. Progesterone should be initiated before week 24 either vaginally or intramuscularly. The uncertainty of whether there is a possible risk for rare but severe neurological dissability in the offspring due to progesterone treatment, must be taken&nbsp;into consideration.",
  "remarks" : "",
  "advice" : "<strong>When to initiate the progesterone supplementation?</strong><br>\nThe included studies initiated the treatment before gestational week 24.<br>\nAs we want to prevent not to treat, early intervention makes sense. Therefore, most obstetricians initiate the treatment in the early second trimester or even in the first trimester of pregnancy.<br>\n&nbsp;<br>\n<strong>When to stop the progesterone supplementation?</strong><br>\nThe included studies stopped the treatment between 34 and 37&nbsp;weeks gestation.&nbsp;Some obstetricians might recommend continuation until 37 gestational weeks, due&nbsp;to Csapo´s progesterone block theory <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[25] Csapo A :  Progesterone block.. The American journal of anatomy 1956;98(2):273-91\" data-pmid=\"\" data-ref-id=\"191625\" data-url=\"\">[25]</cite></span>,&nbsp;i.e. fear of labour contractions as a result of progesterone withdrawal.<br>\n&nbsp;<br>\n<strong>How to administer the progesterone?</strong><br>\nConcerning the reduction of the risk of preterm birth before 34 gestational weeks the two administration forms seem equivalent; a) weekly intramuscular injection of&nbsp;synthetic 17α-hydroxyprogesterone caproate (17OHPC) and b) daily vaginal administration of micronized progesterone.<br>\nThe two studies with the highest weight in the meta-analysis used one daily administration of either&nbsp;90 or 200 mg progesterone vaginally. In order to achieve a more even diurnal progesterone level, some obstetricians prescribe 100 mg twice a day.<br>\nIn the Nordic countries, vaginal administration is standard, whereas intramuscular administration is used in other parts of the world. We found no difference in effect related to administration route. In a meta-analysis (data not shown) combining the 9 studies using either vaginal and intramuscular administration, we found the same effect for reducing risk or preterm birth before week 33-35 (RR 0.66 (0.51-0.85 95%CI). The vaginal administration is easy to use but has the side effect of vaginal discharge and discomfort. In these cases, some obstetricians accept rectal administration. The effect of this administration, however, has never been studied. The intramuscular administration has side effects related to injection site with local skin reactions such as pain, itching and swelling.",
  "rational" : "The majority of the studies includes women with a history of preterm birth before week 37. There is only one study including women with a history of preterm birth before week 34, the Norman study <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span>. The authors of this metaanalysis find it mainly clinically relevant to prevent preterm birth before week 34 and therefore the Norman study was set as comparator in the metaanalysis (see Table 1 below).&nbsp;<br>\n<br>\nBased on the dots given in the section \"Practical information\", we give a weak recommendation in favor of treatment with progesterone in women with a history of preterm birth.\n<ul>\n\t<li>Preterm birth before week 33-35 (weight 7) favored treatment with both vaginal progesterone (RR 0.66; 95%CI 0.46-0.93) and intramuscular progesterone (RR 0.63; 95%CI 0.46-0.85). As the risk of publication bias was high, we recalculated the RR including only the two publications with the highest weights and the lowest risks of bias (RR 0.85; 95%CI 0.70 – 1.04, I 2.0%) <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[58] O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW :  Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2007;30(5):687-96\" data-pmid=\"\" data-ref-id=\"191661\" data-url=\"\">[58]</cite></span>. Furthermore, one of these two studies were also characterized by preterm birth rates closer&nbsp;to the 8.6% found&nbsp;in a Swedish population&nbsp;with a history of preterm birth before week 34,&nbsp;and a repeated preterm birth before week 34&nbsp;(Table 1). We conclude, that in a Nordic population the risk reduction of preterm birth before week 33-35&nbsp;is more likely to be 15% as estimated by the two largest included studies,&nbsp;covering one study in a&nbsp;Nordic population,&nbsp;than the 34% risk reduction found by the meta-analysis of all seven studies.</li>\n\t<li>Adverse long-term effects for the offspring (weight 9) favored placebo (RR 1.35; 95%CI 0.98 – 1.93). However, the evidence was very low. We conclude that this result is of concern.</li>\n\t<li>Maternal adverse effects including cancer (Weight 8): Progesterone may increase the risk of breast cancer in menopausal women. This question has not been addressed in pregnant women in whom we know the progesterone level is already high. We conclude that we cannot ignore this potential risk.</li>\n</ul>\n<br>\n<strong>Table 1. Prevalence of preterm deliveries in the second pregnancy given the gestational duration in the first pregnancy. </strong><br>\n&nbsp;Table presents the fraction of women who experienced preterm delivery (delivery before 34<sup>th</sup> or 37<sup>th</sup> week of gestation) in the second pregnancy given the duration of the first pregnancy. Analyses are based on the data retrieved from the Swedish Medical Birth Register (MFR), on two cohorts. One cohort, includes singletons, both induced and spontaneous deliveries, and cover the births that occurred over the years 1973 – 2012. Second cohort is restricted to spontaneous deliveries, and cover the singleton births that occurred over the years 1990 – 2012. Analyses were run using the best estimate of gestational age provided in the MFR (“The Swedish Medical Birth Register - A Summary of Content and Quality,” n.d.).<br>\n&nbsp;\n<table align=\"left\" border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:700px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:69px\">&nbsp;</td>\n\t\t\t<td style=\"width:49px\">&nbsp;</td>\n\t\t\t<td style=\"width:102px\">&nbsp;</td>\n\t\t\t<td colspan=\"3\" rowspan=\"1\" style=\"text-align:center; width:285px\"><strong>Second child*</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:69px\">&nbsp;</td>\n\t\t\t<td style=\"width:49px\">&nbsp;</td>\n\t\t\t<td style=\"width:102px\">&nbsp;</td>\n\t\t\t<td style=\"text-align:center; width:95px\">Term</td>\n\t\t\t<td colspan=\"2\" rowspan=\"1\" style=\"text-align:center; width:180px\">Preterm</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:69px\">&nbsp;</td>\n\t\t\t<td style=\"width:49px\">&nbsp;</td>\n\t\t\t<td style=\"width:102px\">&nbsp;</td>\n\t\t\t<td style=\"text-align:center; width:95px\">&gt;= 37 weeks<br>\n\t\t\tn (%)</td>\n\t\t\t<td style=\"text-align:center; width:67px\">&lt; 34 weeks<br>\n\t\t\tn (%)</td>\n\t\t\t<td style=\"text-align:center; width:91px\">&lt; 37 weeks<br>\n\t\t\tn (%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"6\"><strong>Years 1973 – 2012, induced and spontaneous deliveries, n = 2 433&nbsp;820</strong><strong> births (two consequtively born singletons) in n =&nbsp;1 216&nbsp;910 mothers.</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"3\" style=\"width:69px\"><strong>First child</strong>*</td>\n\t\t\t<td style=\"width:49px\">Term</td>\n\t\t\t<td style=\"width:102px\">&gt;= 37 weeks,<br>\n\t\t\t1 150&nbsp;814 (100)</td>\n\t\t\t<td style=\"width:95px\">1 116&nbsp;181 (97.0)</td>\n\t\t\t<td style=\"width:67px\">7&nbsp;582 (0.7)</td>\n\t\t\t<td style=\"width:91px\">34&nbsp;633 (3.0)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"2\" style=\"width:49px\">Preterm</td>\n\t\t\t<td style=\"width:102px\">&lt; 34 weeks,<br>\n\t\t\t15 280 (100)</td>\n\t\t\t<td style=\"width:95px\">11&nbsp;590 (75.9)</td>\n\t\t\t<td style=\"width:67px\">1&nbsp;321 (8.6)</td>\n\t\t\t<td style=\"width:91px\">3&nbsp;690 (24.1)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:102px\">&lt; 37 weeks,<br>\n\t\t\t66&nbsp;096 (100)</td>\n\t\t\t<td style=\"width:95px\">55&nbsp;133 (83.4)</td>\n\t\t\t<td style=\"width:67px\">2&nbsp;774 (4.2)</td>\n\t\t\t<td style=\"width:91px\">10 963 (16.5)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"6\" style=\"width:58px\"><strong>Years 1990 – 2012, included only spontaneous deliveries **, n = 925&nbsp;132 births (two consequtively born singletons) in&nbsp;n = 462&nbsp;566 mothers</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"3\" style=\"width:69px\"><strong>First child</strong>*</td>\n\t\t\t<td style=\"width:49px\">Term</td>\n\t\t\t<td style=\"width:102px\">&gt;= 37 weeks,<br>\n\t\t\t440&nbsp;848 (100)</td>\n\t\t\t<td style=\"width:95px\">431&nbsp;492 (97.9)</td>\n\t\t\t<td style=\"width:67px\">1705 (0.4)</td>\n\t\t\t<td style=\"width:91px\">9&nbsp;356 (2.1)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"2\" style=\"width:49px\">Preterm</td>\n\t\t\t<td style=\"width:102px\">&lt; 34 weeks,<br>\n\t\t\t4&nbsp;002 (100)</td>\n\t\t\t<td style=\"width:95px\">2847 (71.1)</td>\n\t\t\t<td style=\"width:67px\">366 (9.1)</td>\n\t\t\t<td style=\"width:91px\">1&nbsp;155 (28.9)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:102px\">&lt; 37 weeks,<br>\n\t\t\t21&nbsp;718 (100)</td>\n\t\t\t<td style=\"width:95px\">18&nbsp;247 (84.0)</td>\n\t\t\t<td style=\"width:67px\">747 (3.4)</td>\n\t\t\t<td style=\"width:91px\">3&nbsp;471 (16.0)</td>\n\t\t</tr>\n\t</tbody>\n</table>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n* order of the child was assessed based on the <u>cleaned/revised</u> variable of parity (included child of 1<sup>st</sup> and 2<sup>nd</sup> parity)<br>\n** the mode of the delivery (induced / spontaneous) has been registered in the MFR since the year 1990<br>\n<br>\nReference: The Swedish Medical Birth Register - A Summary of Content and Quality. (n.d.). Retrieved January 21, 2019, from https://www.socialstyrelsen.se/publikationer2003/2003-112-3",
  "adaptation" : "",
  "showAdaptation" : false,
  "hasData" : {
    "advice" : false,
    "adaptation" : false,
    "decisionAids" : false,
    "discussion" : false,
    "discussionCount" : 0,
    "discussionUnresolvedCount" : 0,
    "keyInfo" : false,
    "emrCodes" : false,
    "evidence" : false,
    "evidenceCount" : 0,
    "rational" : false,
    "references" : false
  },
  "keyInfoType" : "SUMMARY",
  "keyInfoDisplayMode" : "TEXT",
  "shortName" : "jWoK8j",
  "trackHeading" : "",
  "trackText" : "In women with a singleton pregnancy and history of preterm birth before week 37, without an obvious course such as uterine malformation or conization, the administration of progesterone, might be considered in order to reduce the risk of a repeated preterm birth before&nbsp;week 33-35. Progesterone should be initiated before week 24 either vaginally or intramuscularly. The uncertainty of whether there is a possible risk for rare but severe neurological dissability in the offspring due to progesterone treatment, must be taken&nbsp;into consideration.",
  "trackRemarks" : "",
  "trackAdvice" : "<strong>When to initiate the progesterone supplementation?</strong><br>\nThe included studies initiated the treatment before gestational week 24.<br>\nAs we want to prevent not to treat, early intervention makes sense. Therefore, most obstetricians initiate the treatment in the early second trimester or even in the first trimester of pregnancy.<br>\n&nbsp;<br>\n<strong>When to stop the progesterone supplementation?</strong><br>\nThe included studies stopped the treatment between 34 and 37&nbsp;weeks gestation.&nbsp;Some obstetricians might recommend continuation until 37 gestational weeks, due&nbsp;to Csapo´s progesterone block theory <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[25] Csapo A :  Progesterone block.. The American journal of anatomy 1956;98(2):273-91\" data-pmid=\"\" data-ref-id=\"191625\" data-url=\"\">[25]</cite></span>,&nbsp;i.e. fear of labour contractions as a result of progesterone withdrawal.<br>\n&nbsp;<br>\n<strong>How to administer the progesterone?</strong><br>\nConcerning the reduction of the risk of preterm birth before 34 gestational weeks the two administration forms seem equivalent; a) weekly intramuscular injection of&nbsp;synthetic 17α-hydroxyprogesterone caproate (17OHPC) and b) daily vaginal administration of micronized progesterone.<br>\nThe two studies with the highest weight in the meta-analysis used one daily administration of either&nbsp;90 or 200 mg progesterone vaginally. In order to achieve a more even diurnal progesterone level, some obstetricians prescribe 100 mg twice a day.<br>\nIn the Nordic countries, vaginal administration is standard, whereas intramuscular administration is used in other parts of the world. We found no difference in effect related to administration route. In a meta-analysis (data not shown) combining the 9 studies using either vaginal and intramuscular administration, we found the same effect for reducing risk or preterm birth before week 33-35 (RR 0.66 (0.51-0.85 95%CI). The vaginal administration is easy to use but has the side effect of vaginal discharge and discomfort. In these cases, some obstetricians accept rectal administration. The effect of this administration, however, has never been studied. The intramuscular administration has side effects related to injection site with local skin reactions such as pain, itching and swelling.",
  "trackRational" : "The majority of the studies includes women with a history of preterm birth before week 37. There is only one study including women with a history of preterm birth before week 34, the Norman study <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span>. The authors of this metaanalysis find it mainly clinically relevant to prevent preterm birth before week 34 and therefore the Norman study was set as comparator in the metaanalysis (see Table 1 below).&nbsp;<br>\n<br>\nBased on the dots given in the section \"Practical information\", we give a weak recommendation in favor of treatment with progesterone in women with a history of preterm birth.\n<ul>\n\t<li>Preterm birth before week 33-35 (weight 7) favored treatment with both vaginal progesterone (RR 0.66; 95%CI 0.46-0.93) and intramuscular progesterone (RR 0.63; 95%CI 0.46-0.85). As the risk of publication bias was high, we recalculated the RR including only the two publications with the highest weights and the lowest risks of bias (RR 0.85; 95%CI 0.70 – 1.04, I 2.0%) <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[58] O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW :  Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2007;30(5):687-96\" data-pmid=\"\" data-ref-id=\"191661\" data-url=\"\">[58]</cite></span>. Furthermore, one of these two studies were also characterized by preterm birth rates closer&nbsp;to the 8.6% found&nbsp;in a Swedish population&nbsp;with a history of preterm birth before week 34,&nbsp;and a repeated preterm birth before week 34&nbsp;(Table 1). We conclude, that in a Nordic population the risk reduction of preterm birth before week 33-35&nbsp;is more likely to be 15% as estimated by the two largest included studies,&nbsp;covering one study in a&nbsp;Nordic population,&nbsp;than the 34% risk reduction found by the meta-analysis of all seven studies.</li>\n\t<li>Adverse long-term effects for the offspring (weight 9) favored placebo (RR 1.35; 95%CI 0.98 – 1.93). However, the evidence was very low. We conclude that this result is of concern.</li>\n\t<li>Maternal adverse effects including cancer (Weight 8): Progesterone may increase the risk of breast cancer in menopausal women. This question has not been addressed in pregnant women in whom we know the progesterone level is already high. We conclude that we cannot ignore this potential risk.</li>\n</ul>\n<br>\n<strong>Table 1. Prevalence of preterm deliveries in the second pregnancy given the gestational duration in the first pregnancy. </strong><br>\n&nbsp;Table presents the fraction of women who experienced preterm delivery (delivery before 34<sup>th</sup> or 37<sup>th</sup> week of gestation) in the second pregnancy given the duration of the first pregnancy. Analyses are based on the data retrieved from the Swedish Medical Birth Register (MFR), on two cohorts. One cohort, includes singletons, both induced and spontaneous deliveries, and cover the births that occurred over the years 1973 – 2012. Second cohort is restricted to spontaneous deliveries, and cover the singleton births that occurred over the years 1990 – 2012. Analyses were run using the best estimate of gestational age provided in the MFR (“The Swedish Medical Birth Register - A Summary of Content and Quality,” n.d.).<br>\n&nbsp;\n<table align=\"left\" border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:700px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:69px\">&nbsp;</td>\n\t\t\t<td style=\"width:49px\">&nbsp;</td>\n\t\t\t<td style=\"width:102px\">&nbsp;</td>\n\t\t\t<td colspan=\"3\" rowspan=\"1\" style=\"text-align:center; width:285px\"><strong>Second child*</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:69px\">&nbsp;</td>\n\t\t\t<td style=\"width:49px\">&nbsp;</td>\n\t\t\t<td style=\"width:102px\">&nbsp;</td>\n\t\t\t<td style=\"text-align:center; width:95px\">Term</td>\n\t\t\t<td colspan=\"2\" rowspan=\"1\" style=\"text-align:center; width:180px\">Preterm</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:69px\">&nbsp;</td>\n\t\t\t<td style=\"width:49px\">&nbsp;</td>\n\t\t\t<td style=\"width:102px\">&nbsp;</td>\n\t\t\t<td style=\"text-align:center; width:95px\">&gt;= 37 weeks<br>\n\t\t\tn (%)</td>\n\t\t\t<td style=\"text-align:center; width:67px\">&lt; 34 weeks<br>\n\t\t\tn (%)</td>\n\t\t\t<td style=\"text-align:center; width:91px\">&lt; 37 weeks<br>\n\t\t\tn (%)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"6\"><strong>Years 1973 – 2012, induced and spontaneous deliveries, n = 2 433&nbsp;820</strong><strong> births (two consequtively born singletons) in n =&nbsp;1 216&nbsp;910 mothers.</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"3\" style=\"width:69px\"><strong>First child</strong>*</td>\n\t\t\t<td style=\"width:49px\">Term</td>\n\t\t\t<td style=\"width:102px\">&gt;= 37 weeks,<br>\n\t\t\t1 150&nbsp;814 (100)</td>\n\t\t\t<td style=\"width:95px\">1 116&nbsp;181 (97.0)</td>\n\t\t\t<td style=\"width:67px\">7&nbsp;582 (0.7)</td>\n\t\t\t<td style=\"width:91px\">34&nbsp;633 (3.0)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"2\" style=\"width:49px\">Preterm</td>\n\t\t\t<td style=\"width:102px\">&lt; 34 weeks,<br>\n\t\t\t15 280 (100)</td>\n\t\t\t<td style=\"width:95px\">11&nbsp;590 (75.9)</td>\n\t\t\t<td style=\"width:67px\">1&nbsp;321 (8.6)</td>\n\t\t\t<td style=\"width:91px\">3&nbsp;690 (24.1)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:102px\">&lt; 37 weeks,<br>\n\t\t\t66&nbsp;096 (100)</td>\n\t\t\t<td style=\"width:95px\">55&nbsp;133 (83.4)</td>\n\t\t\t<td style=\"width:67px\">2&nbsp;774 (4.2)</td>\n\t\t\t<td style=\"width:91px\">10 963 (16.5)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"6\" style=\"width:58px\"><strong>Years 1990 – 2012, included only spontaneous deliveries **, n = 925&nbsp;132 births (two consequtively born singletons) in&nbsp;n = 462&nbsp;566 mothers</strong></td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"3\" style=\"width:69px\"><strong>First child</strong>*</td>\n\t\t\t<td style=\"width:49px\">Term</td>\n\t\t\t<td style=\"width:102px\">&gt;= 37 weeks,<br>\n\t\t\t440&nbsp;848 (100)</td>\n\t\t\t<td style=\"width:95px\">431&nbsp;492 (97.9)</td>\n\t\t\t<td style=\"width:67px\">1705 (0.4)</td>\n\t\t\t<td style=\"width:91px\">9&nbsp;356 (2.1)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td colspan=\"1\" rowspan=\"2\" style=\"width:49px\">Preterm</td>\n\t\t\t<td style=\"width:102px\">&lt; 34 weeks,<br>\n\t\t\t4&nbsp;002 (100)</td>\n\t\t\t<td style=\"width:95px\">2847 (71.1)</td>\n\t\t\t<td style=\"width:67px\">366 (9.1)</td>\n\t\t\t<td style=\"width:91px\">1&nbsp;155 (28.9)</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:102px\">&lt; 37 weeks,<br>\n\t\t\t21&nbsp;718 (100)</td>\n\t\t\t<td style=\"width:95px\">18&nbsp;247 (84.0)</td>\n\t\t\t<td style=\"width:67px\">747 (3.4)</td>\n\t\t\t<td style=\"width:91px\">3&nbsp;471 (16.0)</td>\n\t\t</tr>\n\t</tbody>\n</table>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n<br>\n* order of the child was assessed based on the <u>cleaned/revised</u> variable of parity (included child of 1<sup>st</sup> and 2<sup>nd</sup> parity)<br>\n** the mode of the delivery (induced / spontaneous) has been registered in the MFR since the year 1990<br>\n<br>\nReference: The Swedish Medical Birth Register - A Summary of Content and Quality. (n.d.). Retrieved January 21, 2019, from https://www.socialstyrelsen.se/publikationer2003/2003-112-3",
  "trackAdaptation" : "",
  "keyInfo" : {
    "keyInfoType" : "SUMMARY",
    "recommendationId" : 51119,
    "benefits" : "<strong>Preterm birth</strong><br>\nIn women with a history of preterm birth, there is only an expected small effect due to the low risk of unexplained preterm birth in a Nordic population. It is especially preterm birth before week 34 that is associated with an increased risk of morbidity and mortality, and these cases may be the ones most likely to benefit from progesterone treatment&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[74]  UpToDate Progesterone.\" data-pmid=\"\" data-ref-id=\"191670\" data-url=\"\">[74]</cite></span>. We did not find studies evaluating whether there might be an additive effect for reducing late preterm birth by continuing progesterone treatment until week 37.&nbsp;<br>\n<br>\n<strong>Long-term (2 years) mortality and morbidity in infants, including cerebral palsy</strong>\n\n<ul>\n\t<li>Primary outcome: Only one placebo-controlled randomized trial (The OPPTIMUM study) included long-term childhood outcome as one of their primary outcomes <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span>. ]: a composite outcome of death or moderate to severe neurodevelopmental impairment at two years of age. This outcome favored placebo (12% risk) over progesterone (17%). However, the difference was not statistically significant: OR of 1.45 (95% CI 0.98 – 2.15; p = 0.064). Thus, this study indicates that progesterone does not improve this long-term outcome, in fact it might even worsen the outcome.</li>\n\t<li>Secondary analysis: Secondary analysis of the Meis study <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[30] Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast J-A, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson GD,  :  Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.. Obstetrics and gynecology 2007;110(4):865-72\" data-pmid=\"\" data-ref-id=\"191633\" data-url=\"\">[30]</cite></span>,&nbsp;where children underwent a physical examination at a mean follow-up of 48 months of age, showed no difference between the progesterone and placebo group with regard to health status, physical examination or neurophysiological development evaluated by the Ages and Stages Questionnaire.</li>\n\t<li>Twin studies: Secondary analyses of two twin studies did not find evidence of neither benefit nor harm of second and third trimester progesterone exposure regarding neurophysiological development at up to 6 years of age&nbsp;&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[83] Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A :  Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(3):272-80\" data-pmid=\"\" data-ref-id=\"191682\" data-url=\"\">[83]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[31] McNamara HC, Wood R, Chalmers J, Marlow N, Norrie J, MacLennan G, McPherson G, Boachie C, Norman JE :  STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome.. PloS one 2015;10(4):e0122341\" data-pmid=\"\" data-ref-id=\"191635\" data-url=\"\">[31]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[32] Vedel C, Larsen H, Holmskov A, Andreasen KR, Uldbjerg N, Ramb J, Bødker B, Skibsted L, Sperling L, Krebs L, Zingenberg H, Laursen L, Christensen JT, Tabor A, Rode L :  Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in&nbsp;twins up to 8 years of age.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2016;48(3):382-9\" data-pmid=\"\" data-ref-id=\"191634\" data-url=\"\">[32]</cite></span>.</li>\n</ul>\n<br>\n<strong>Serious maternal adverse effects, including cancer</strong><br>\nSerious maternal adverse effects like deaths or risk of cancer – No reports on increased risk in pregnant women.\n<ul>\n\t<li>Primary outcome: No studies.</li>\n\t<li>Secondary outcome: No studies.</li>\n\t<li>Concern: Trials on menopause hormone therapy indicate an association between progesterone treatment and increased risk of breast cancer <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[28]  Joshi PA, Goodwin PJ, Khokha R :  Progesterone Exposure and Breast Cancer Risk: Understanding the Biological Roots.. JAMA oncology 2015;1(3):283-5\" data-pmid=\"\" data-ref-id=\"191630\" data-url=\"\">[28]</cite></span>.</li>\n</ul>\nGestational diabetes – No increased risk. However, the evidence is low.\n\n<ul>\n\t<li>Primary outcome: No studies.</li>\n\t<li>Secondary analysis - RCT on singleton pregnancies: One study on intramuscular 17-OHPC found an RR 1.23 (95% CI 0.52-2.89; N = 1094)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[33] Gyamfi C, Horton AL, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Meis PJ, Spong CY, Dombrowski M, Sibai B, Varner MW, Iams JD, Mercer BM, Carpenter MW, Lo J, Ramin SM, O'Sullivan MJ, Miodovnik M, Conway D :  The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.. American journal of obstetrics and gynecology 2009;201(4):392.e1-5\" data-pmid=\"\" data-ref-id=\"191636\" data-url=\"\">[33]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[34] Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S,  :  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.. The New England journal of medicine 2003;348(24):2379-85\" data-pmid=\"\" data-ref-id=\"191632\" data-url=\"\">[34]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[35] Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, Saltzman DH :  Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.. Diabetes care 2007;30(9):2277-80\" data-pmid=\"\" data-ref-id=\"191637\" data-url=\"\">[35]</cite></span></li>\n\t<li>Secondary outcome - RCT in twin pregnancies: One study on vaginal progesterone found OR 1.4 (95%CI 0.6-3.0)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[83] Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A :  Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(3):272-80\" data-pmid=\"\" data-ref-id=\"191682\" data-url=\"\">[83, ]</cite></span>&nbsp;and two studies on 17-OHPC found RR 0.98 (95%CI 0.57-1.68)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[36] Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G :  A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.. The New England journal of medicine 2007;357(5):454-61\" data-pmid=\"\" data-ref-id=\"191638\" data-url=\"\">[36]</cite></span>&nbsp;and OR 0.99 (0.35-2.78)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[37] Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenwold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW :  17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.. Obstetrics and gynecology 2011;118(3):513-20\" data-pmid=\"\" data-ref-id=\"191639\" data-url=\"\">[37.]</cite></span></li>\n</ul>\n",
    "trackBenefits" : "<strong>Preterm birth</strong><br>\nIn women with a history of preterm birth, there is only an expected small effect due to the low risk of unexplained preterm birth in a Nordic population. It is especially preterm birth before week 34 that is associated with an increased risk of morbidity and mortality, and these cases may be the ones most likely to benefit from progesterone treatment&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[74]  UpToDate Progesterone.\" data-pmid=\"\" data-ref-id=\"191670\" data-url=\"\">[74]</cite></span>. We did not find studies evaluating whether there might be an additive effect for reducing late preterm birth by continuing progesterone treatment until week 37.&nbsp;<br>\n<br>\n<strong>Long-term (2 years) mortality and morbidity in infants, including cerebral palsy</strong>\n\n<ul>\n\t<li>Primary outcome: Only one placebo-controlled randomized trial (The OPPTIMUM study) included long-term childhood outcome as one of their primary outcomes <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span>. ]: a composite outcome of death or moderate to severe neurodevelopmental impairment at two years of age. This outcome favored placebo (12% risk) over progesterone (17%). However, the difference was not statistically significant: OR of 1.45 (95% CI 0.98 – 2.15; p = 0.064). Thus, this study indicates that progesterone does not improve this long-term outcome, in fact it might even worsen the outcome.</li>\n\t<li>Secondary analysis: Secondary analysis of the Meis study <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[30] Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast J-A, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson GD,  :  Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.. Obstetrics and gynecology 2007;110(4):865-72\" data-pmid=\"\" data-ref-id=\"191633\" data-url=\"\">[30]</cite></span>,&nbsp;where children underwent a physical examination at a mean follow-up of 48 months of age, showed no difference between the progesterone and placebo group with regard to health status, physical examination or neurophysiological development evaluated by the Ages and Stages Questionnaire.</li>\n\t<li>Twin studies: Secondary analyses of two twin studies did not find evidence of neither benefit nor harm of second and third trimester progesterone exposure regarding neurophysiological development at up to 6 years of age&nbsp;&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[83] Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A :  Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(3):272-80\" data-pmid=\"\" data-ref-id=\"191682\" data-url=\"\">[83]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[31] McNamara HC, Wood R, Chalmers J, Marlow N, Norrie J, MacLennan G, McPherson G, Boachie C, Norman JE :  STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome.. PloS one 2015;10(4):e0122341\" data-pmid=\"\" data-ref-id=\"191635\" data-url=\"\">[31]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[32] Vedel C, Larsen H, Holmskov A, Andreasen KR, Uldbjerg N, Ramb J, Bødker B, Skibsted L, Sperling L, Krebs L, Zingenberg H, Laursen L, Christensen JT, Tabor A, Rode L :  Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in&nbsp;twins up to 8 years of age.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2016;48(3):382-9\" data-pmid=\"\" data-ref-id=\"191634\" data-url=\"\">[32]</cite></span>.</li>\n</ul>\n<br>\n<strong>Serious maternal adverse effects, including cancer</strong><br>\nSerious maternal adverse effects like deaths or risk of cancer – No reports on increased risk in pregnant women.\n<ul>\n\t<li>Primary outcome: No studies.</li>\n\t<li>Secondary outcome: No studies.</li>\n\t<li>Concern: Trials on menopause hormone therapy indicate an association between progesterone treatment and increased risk of breast cancer <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[28]  Joshi PA, Goodwin PJ, Khokha R :  Progesterone Exposure and Breast Cancer Risk: Understanding the Biological Roots.. JAMA oncology 2015;1(3):283-5\" data-pmid=\"\" data-ref-id=\"191630\" data-url=\"\">[28]</cite></span>.</li>\n</ul>\nGestational diabetes – No increased risk. However, the evidence is low.\n\n<ul>\n\t<li>Primary outcome: No studies.</li>\n\t<li>Secondary analysis - RCT on singleton pregnancies: One study on intramuscular 17-OHPC found an RR 1.23 (95% CI 0.52-2.89; N = 1094)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[33] Gyamfi C, Horton AL, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Meis PJ, Spong CY, Dombrowski M, Sibai B, Varner MW, Iams JD, Mercer BM, Carpenter MW, Lo J, Ramin SM, O'Sullivan MJ, Miodovnik M, Conway D :  The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.. American journal of obstetrics and gynecology 2009;201(4):392.e1-5\" data-pmid=\"\" data-ref-id=\"191636\" data-url=\"\">[33]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[34] Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S,  :  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.. The New England journal of medicine 2003;348(24):2379-85\" data-pmid=\"\" data-ref-id=\"191632\" data-url=\"\">[34]</cite></span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[35] Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, Saltzman DH :  Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.. Diabetes care 2007;30(9):2277-80\" data-pmid=\"\" data-ref-id=\"191637\" data-url=\"\">[35]</cite></span></li>\n\t<li>Secondary outcome - RCT in twin pregnancies: One study on vaginal progesterone found OR 1.4 (95%CI 0.6-3.0)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[83] Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A :  Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(3):272-80\" data-pmid=\"\" data-ref-id=\"191682\" data-url=\"\">[83, ]</cite></span>&nbsp;and two studies on 17-OHPC found RR 0.98 (95%CI 0.57-1.68)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[36] Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G :  A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.. The New England journal of medicine 2007;357(5):454-61\" data-pmid=\"\" data-ref-id=\"191638\" data-url=\"\">[36]</cite></span>&nbsp;and OR 0.99 (0.35-2.78)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[37] Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenwold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW :  17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.. Obstetrics and gynecology 2011;118(3):513-20\" data-pmid=\"\" data-ref-id=\"191639\" data-url=\"\">[37.]</cite></span></li>\n</ul>\n",
    "evidence" : "We evaluate the certainty of the evidence to be low due to indirectness (population dissimilarity),&nbsp;low certainty in effect estimate, high risk of publication bias and due to lower risk of spontaneous preterm birth in Nordic countries compared to the majority of the included studies.",
    "trackEvidence" : "We evaluate the certainty of the evidence to be low due to indirectness (population dissimilarity),&nbsp;low certainty in effect estimate, high risk of publication bias and due to lower risk of spontaneous preterm birth in Nordic countries compared to the majority of the included studies.",
    "preferences" : "",
    "trackPreferences" : null,
    "resources" : "<strong>Economy</strong><br>\nIn the decision on whether to treat or not, the treatment related cost need to be compared&nbsp;to the cost per child born preterm. In Denmark, the treatment with vaginal progesterone from week 16 will cost 400 Euro, whereas an uncomplicated&nbsp;on the neonatal ward of a child born between 32 to 35 weeks will cost 10,000 Euro in total.",
    "trackResources" : "<strong>Economy</strong><br>\nIn the decision on whether to treat or not, the treatment related cost need to be compared&nbsp;to the cost per child born preterm. In Denmark, the treatment with vaginal progesterone from week 16 will cost 400 Euro, whereas an uncomplicated&nbsp;on the neonatal ward of a child born between 32 to 35 weeks will cost 10,000 Euro in total.",
    "benefitsStrength" : "WEAK",
    "evidenceStrength" : "WEAK",
    "preferencesStrength" : "STRONG",
    "resourcesStrength" : "STRONG",
    "interventions" : [ ],
    "links" : [ ]
  },
  "referenceId" : [ 191631, 191633, 191642, 191635, 191634, 191636, 191632, 191637, 191638, 191639, 191640, 191682 ],
  "picoId" : [ 53670, 53671 ],
  "links" : [ ]
}, {
  "recommendationId" : 51120,
  "shortCode" : "Eemk7E",
  "guidelineId" : 3384,
  "sectionId" : 41934,
  "order" : 1,
  "strength" : "WEAK",
  "status" : "NOTSET",
  "heading" : "",
  "text" : "In women with a singleton pregnancy before week 25 and a short cervix below 25 mm, vaginal progesterone administration should be considered in order to reduce risk for preterm birth before week 33-35.&nbsp;The uncertainty of whether there is a possible risk for rare but severe neurological dissability in the offspring due to progesterone treatment, must be taken&nbsp;into consideration.<br>\n&nbsp;",
  "remarks" : "",
  "advice" : "<ul>\n\t<li>We included studies on women with a short cervix (&lt;&nbsp;25 mm before week 25) with or without a history of preterm birth.</li>\n\t<li>We excluded studies including women with symptoms of preterm birth (contractions and bleeding).</li>\n\t<li>In the primary PICO we wanted to explore the effect of progesterone in women with no symptoms, no history and so on. However, no studies fulfilled these criteria. Furthermore, we do not recommend screening for short cervix in the&nbsp;general population due to low prevalence of asymptomatic short cervix (see Table 2 below) and low prevalence of preterm birth&nbsp;before week 34 in the Nordic countries (see Table 1 in Rationale for \"Progesterone for women with history of preterm birth\").</li>\n\t<li>The primary outcome was initially set as \"delivery before 34 weeks\". However, we included studies with information&nbsp;on preterm delivery from 33 +0 to 35 +0 weeks due to lack of studies only addressing delivery before 34 weeks gestation.</li>\n</ul>\n<br>\n<strong>Table 2. Summary of studies on cervical length</strong>\n\n<table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:700px\">\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\"col\" style=\"width:92px\">Study</th>\n\t\t\t<th scope=\"col\" style=\"width:72px\">Cut off<br>\n\t\t\t(mm)</th>\n\t\t\t<th scope=\"col\" style=\"width:130px\">Week for cervical screening</th>\n\t\t\t<th scope=\"col\" style=\"width:185px\">Location</th>\n\t\t\t<th scope=\"col\" style=\"width:73px\">Number of women screened</th>\n\t\t\t<th scope=\"col\" style=\"width:80px\">Prevalence</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">To <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[22] To MS, Fonseca EB, Molina FS, Cacho AM, Nicolaides KH :  Maternal characteristics and cervical length in the prediction of spontaneous early preterm delivery in twins.. American journal of obstetrics and gynecology 2006;194(5):1360-5\" data-pmid=\"\" data-ref-id=\"191623\" data-url=\"\">[22]</cite></span></td>\n\t\t\t<td colspan=\"1\" rowspan=\"2\" style=\"width:62px\">&lt;15</td>\n\t\t\t<td style=\"width:120px\">22-24</td>\n\t\t\t<td style=\"width:175px\">UK, Europe, South America</td>\n\t\t\t<td style=\"width:63px\">47 143</td>\n\t\t\t<td style=\"width:70px\">1.1%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Fonseca&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[40] Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH :  Progesterone and the risk of preterm birth among women with a short cervix.. The New England journal of medicine 2007;357(5):462-9\" data-pmid=\"\" data-ref-id=\"191643\" data-url=\"\">[40]</cite></span></td>\n\t\t\t<td style=\"width:120px\">20-25</td>\n\t\t\t<td style=\"width:175px\">UK, South America</td>\n\t\t\t<td style=\"width:63px\">24 620</td>\n\t\t\t<td style=\"width:70px\">1.7%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Hassan&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[41] Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW :  Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(1):18-31\" data-pmid=\"\" data-ref-id=\"191642\" data-url=\"\">[41]</cite></span></td>\n\t\t\t<td style=\"width:62px\">10-20</td>\n\t\t\t<td style=\"width:120px\">20-23</td>\n\t\t\t<td style=\"width:175px\">UK, Europe, 10 countries</td>\n\t\t\t<td style=\"width:63px\">32 091</td>\n\t\t\t<td style=\"width:70px\">2.3%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Heath <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[15] Heath VC, Southall TR, Souka AP, Elisseou A, Nicolaides KH :  Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 1998;12(5):312-7\" data-pmid=\"\" data-ref-id=\"191618\" data-url=\"\">[15]</cite></span></td>\n\t\t\t<td colspan=\"1\" rowspan=\"5\" style=\"width:62px\">&lt;25</td>\n\t\t\t<td style=\"width:120px\">22-23</td>\n\t\t\t<td style=\"width:175px\">London</td>\n\t\t\t<td style=\"width:63px\">2 713</td>\n\t\t\t<td style=\"width:70px\">8.1%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Goya <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[42] Goya M, Pratcorona L, Higueras T, Perez-Hoyos S, Carreras E, Cabero L :  Sonographic cervical length measurement in pregnant women with a cervical pessary.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(2):205-9\" data-pmid=\"\" data-ref-id=\"191647\" data-url=\"\">[42]</cite></span></td>\n\t\t\t<td style=\"width:120px\">18-22</td>\n\t\t\t<td style=\"width:175px\">Spain</td>\n\t\t\t<td style=\"width:63px\">11 518</td>\n\t\t\t<td style=\"width:70px\">6.4%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Taipale <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[17] Taipale P, Hiilesmaa V :  Sonographic measurement of uterine cervix at 18-22 weeks' gestation and the risk of preterm delivery.. Obstetrics and gynecology 1998;92(6):902-7\" data-pmid=\"\" data-ref-id=\"191620\" data-url=\"\">[17]</cite></span></td>\n\t\t\t<td style=\"width:120px\">18-22</td>\n\t\t\t<td style=\"width:175px\">Finland</td>\n\t\t\t<td style=\"width:63px\">3 694</td>\n\t\t\t<td style=\"width:70px\">0.2%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Wulff <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[43] Wulff CB, Rode L, Rosthøj S, Hoseth E, Petersen OB, Tabor A :  Transvaginal sonographic cervical length in first and second trimesters in a low-risk population: a prospective study.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2018;51(5):604-613\" data-pmid=\"\" data-ref-id=\"191645\" data-url=\"\">[43]</cite></span></td>\n\t\t\t<td style=\"width:120px\">19-21</td>\n\t\t\t<td style=\"width:175px\">Denmark</td>\n\t\t\t<td style=\"width:63px\">3 334</td>\n\t\t\t<td style=\"width:70px\">0.8%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Kuusela <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[18] Kuusela P, Jacobsson BO, Söderlund M, Bejlum C, Almström E, Ladfors L, Hagberg H, Wennerholm U-B :  Transvaginal sonographic evaluation of cervical length in the second trimester of asymptomatic singleton pregnancies, and the risk of preterm delivery.. Acta obstetricia et gynecologica Scandinavica 2015;94(6):598-607\" data-pmid=\"\" data-ref-id=\"191621\" data-url=\"\">[18]</cite></span></td>\n\t\t\t<td style=\"width:120px\">16-23</td>\n\t\t\t<td style=\"width:175px\">Sweden</td>\n\t\t\t<td style=\"width:63px\">2 122</td>\n\t\t\t<td style=\"width:70px\">0.5%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Kuusela <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[18] Kuusela P, Jacobsson BO, Söderlund M, Bejlum C, Almström E, Ladfors L, Hagberg H, Wennerholm U-B :  Transvaginal sonographic evaluation of cervical length in the second trimester of asymptomatic singleton pregnancies, and the risk of preterm delivery.. Acta obstetricia et gynecologica Scandinavica 2015;94(6):598-607\" data-pmid=\"\" data-ref-id=\"191621\" data-url=\"\">[18]</cite></span></td>\n\t\t\t<td colspan=\"1\" rowspan=\"3\" style=\"width:62px\">&lt;30</td>\n\t\t\t<td style=\"width:120px\">16-23</td>\n\t\t\t<td style=\"width:175px\">Sweden</td>\n\t\t\t<td style=\"width:63px\">2 122</td>\n\t\t\t<td style=\"width:70px\">3.4%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">van Os <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[44] van Os MA, van der Ven AJ, Kleinrouweler CE, Schuit E, Kazemier BM, Verhoeven CJ, de Miranda E, van Wassenaer-Leemhuis AG, Sikkema JM, Woiski MD, Bossuyt PM, Pajkrt E, de Groot CJM, Mol BWJ, Haak MC :  Preventing Preterm Birth with Progesterone in Women with a Short Cervical Length from a Low-Risk Population: A Multicenter Double-Blind Placebo-Controlled Randomized Trial.. American journal of perinatology 2015;32(10):993-1000\" data-pmid=\"\" data-ref-id=\"191644\" data-url=\"\">[44]</cite></span></td>\n\t\t\t<td style=\"width:120px\">18-22</td>\n\t\t\t<td style=\"width:175px\">Holland</td>\n\t\t\t<td style=\"width:63px\">20 234</td>\n\t\t\t<td style=\"width:70px\">0.2%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Grobman <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[45] Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, Tita ATN, Rouse DJ, Sorokin Y, Wapner RJ, Leveno KJ, Blackwell S, Esplin MS, Tolosa JE, Thorp JM, Caritis SN, Van Dorsten JP,  :  17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.. American journal of obstetrics and gynecology 2012;207(5):390.e1-8\" data-pmid=\"\" data-ref-id=\"191646\" data-url=\"\">[45]</cite></span></td>\n\t\t\t<td style=\"width:120px\">16-22</td>\n\t\t\t<td style=\"width:175px\">USA</td>\n\t\t\t<td style=\"width:63px\">15 435</td>\n\t\t\t<td style=\"width:70px\">10%</td>\n\t\t</tr>\n\t</tbody>\n</table>\n<br>\n<strong>When to initiate the progesterone supplementation?</strong><br>\nThe included studies initiated the treatment before gestational week 25 in case of cervix length below 25 mm.&nbsp;<br>\n&nbsp;<br>\n<strong>When to stop the progesterone supplementation?</strong><br>\nThe included studies stopped the treatment between 34 and 37&nbsp;weeks gestation.&nbsp;Some obstetricians might recommend continuation until 37 gestational week, due&nbsp;to Csapo´s progesterone block theory&nbsp;[25],&nbsp;i.e. fear of labour contractions as a result of progesterone withdrawal.",
  "rational" : "The majority of studies includes women with a history of preterm birth before week 37. There is only one study including women with a history of preterm birth before week 34, the Norman study <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span>. We find it mainly clinically relevant to prevent preterm birth before week 34 and therefore the Norman study was set as a comparator in the meta-analysis.",
  "adaptation" : "",
  "showAdaptation" : false,
  "hasData" : {
    "advice" : false,
    "adaptation" : false,
    "decisionAids" : false,
    "discussion" : false,
    "discussionCount" : 0,
    "discussionUnresolvedCount" : 0,
    "keyInfo" : false,
    "emrCodes" : false,
    "evidence" : false,
    "evidenceCount" : 0,
    "rational" : false,
    "references" : false
  },
  "keyInfoType" : "SUMMARY",
  "keyInfoDisplayMode" : "TEXT",
  "shortName" : "Eemk7E",
  "trackHeading" : "",
  "trackText" : "In women with a singleton pregnancy before week 25 and a short cervix below 25 mm, vaginal progesterone administration should be considered in order to reduce risk for preterm birth before week 33-35.&nbsp;The uncertainty of whether there is a possible risk for rare but severe neurological dissability in the offspring due to progesterone treatment, must be taken&nbsp;into consideration.<br>\n&nbsp;",
  "trackRemarks" : "",
  "trackAdvice" : "<ul>\n\t<li>We included studies on women with a short cervix (&lt;&nbsp;25 mm before week 25) with or without a history of preterm birth.</li>\n\t<li>We excluded studies including women with symptoms of preterm birth (contractions and bleeding).</li>\n\t<li>In the primary PICO we wanted to explore the effect of progesterone in women with no symptoms, no history and so on. However, no studies fulfilled these criteria. Furthermore, we do not recommend screening for short cervix in the&nbsp;general population due to low prevalence of asymptomatic short cervix (see Table 2 below) and low prevalence of preterm birth&nbsp;before week 34 in the Nordic countries (see Table 1 in Rationale for \"Progesterone for women with history of preterm birth\").</li>\n\t<li>The primary outcome was initially set as \"delivery before 34 weeks\". However, we included studies with information&nbsp;on preterm delivery from 33 +0 to 35 +0 weeks due to lack of studies only addressing delivery before 34 weeks gestation.</li>\n</ul>\n<br>\n<strong>Table 2. Summary of studies on cervical length</strong>\n\n<table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:700px\">\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\"col\" style=\"width:92px\">Study</th>\n\t\t\t<th scope=\"col\" style=\"width:72px\">Cut off<br>\n\t\t\t(mm)</th>\n\t\t\t<th scope=\"col\" style=\"width:130px\">Week for cervical screening</th>\n\t\t\t<th scope=\"col\" style=\"width:185px\">Location</th>\n\t\t\t<th scope=\"col\" style=\"width:73px\">Number of women screened</th>\n\t\t\t<th scope=\"col\" style=\"width:80px\">Prevalence</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">To <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[22] To MS, Fonseca EB, Molina FS, Cacho AM, Nicolaides KH :  Maternal characteristics and cervical length in the prediction of spontaneous early preterm delivery in twins.. American journal of obstetrics and gynecology 2006;194(5):1360-5\" data-pmid=\"\" data-ref-id=\"191623\" data-url=\"\">[22]</cite></span></td>\n\t\t\t<td colspan=\"1\" rowspan=\"2\" style=\"width:62px\">&lt;15</td>\n\t\t\t<td style=\"width:120px\">22-24</td>\n\t\t\t<td style=\"width:175px\">UK, Europe, South America</td>\n\t\t\t<td style=\"width:63px\">47 143</td>\n\t\t\t<td style=\"width:70px\">1.1%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Fonseca&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[40] Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH :  Progesterone and the risk of preterm birth among women with a short cervix.. The New England journal of medicine 2007;357(5):462-9\" data-pmid=\"\" data-ref-id=\"191643\" data-url=\"\">[40]</cite></span></td>\n\t\t\t<td style=\"width:120px\">20-25</td>\n\t\t\t<td style=\"width:175px\">UK, South America</td>\n\t\t\t<td style=\"width:63px\">24 620</td>\n\t\t\t<td style=\"width:70px\">1.7%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Hassan&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[41] Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW :  Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(1):18-31\" data-pmid=\"\" data-ref-id=\"191642\" data-url=\"\">[41]</cite></span></td>\n\t\t\t<td style=\"width:62px\">10-20</td>\n\t\t\t<td style=\"width:120px\">20-23</td>\n\t\t\t<td style=\"width:175px\">UK, Europe, 10 countries</td>\n\t\t\t<td style=\"width:63px\">32 091</td>\n\t\t\t<td style=\"width:70px\">2.3%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Heath <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[15] Heath VC, Southall TR, Souka AP, Elisseou A, Nicolaides KH :  Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 1998;12(5):312-7\" data-pmid=\"\" data-ref-id=\"191618\" data-url=\"\">[15]</cite></span></td>\n\t\t\t<td colspan=\"1\" rowspan=\"5\" style=\"width:62px\">&lt;25</td>\n\t\t\t<td style=\"width:120px\">22-23</td>\n\t\t\t<td style=\"width:175px\">London</td>\n\t\t\t<td style=\"width:63px\">2 713</td>\n\t\t\t<td style=\"width:70px\">8.1%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Goya <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[42] Goya M, Pratcorona L, Higueras T, Perez-Hoyos S, Carreras E, Cabero L :  Sonographic cervical length measurement in pregnant women with a cervical pessary.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2011;38(2):205-9\" data-pmid=\"\" data-ref-id=\"191647\" data-url=\"\">[42]</cite></span></td>\n\t\t\t<td style=\"width:120px\">18-22</td>\n\t\t\t<td style=\"width:175px\">Spain</td>\n\t\t\t<td style=\"width:63px\">11 518</td>\n\t\t\t<td style=\"width:70px\">6.4%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Taipale <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[17] Taipale P, Hiilesmaa V :  Sonographic measurement of uterine cervix at 18-22 weeks' gestation and the risk of preterm delivery.. Obstetrics and gynecology 1998;92(6):902-7\" data-pmid=\"\" data-ref-id=\"191620\" data-url=\"\">[17]</cite></span></td>\n\t\t\t<td style=\"width:120px\">18-22</td>\n\t\t\t<td style=\"width:175px\">Finland</td>\n\t\t\t<td style=\"width:63px\">3 694</td>\n\t\t\t<td style=\"width:70px\">0.2%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Wulff <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[43] Wulff CB, Rode L, Rosthøj S, Hoseth E, Petersen OB, Tabor A :  Transvaginal sonographic cervical length in first and second trimesters in a low-risk population: a prospective study.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2018;51(5):604-613\" data-pmid=\"\" data-ref-id=\"191645\" data-url=\"\">[43]</cite></span></td>\n\t\t\t<td style=\"width:120px\">19-21</td>\n\t\t\t<td style=\"width:175px\">Denmark</td>\n\t\t\t<td style=\"width:63px\">3 334</td>\n\t\t\t<td style=\"width:70px\">0.8%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Kuusela <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[18] Kuusela P, Jacobsson BO, Söderlund M, Bejlum C, Almström E, Ladfors L, Hagberg H, Wennerholm U-B :  Transvaginal sonographic evaluation of cervical length in the second trimester of asymptomatic singleton pregnancies, and the risk of preterm delivery.. Acta obstetricia et gynecologica Scandinavica 2015;94(6):598-607\" data-pmid=\"\" data-ref-id=\"191621\" data-url=\"\">[18]</cite></span></td>\n\t\t\t<td style=\"width:120px\">16-23</td>\n\t\t\t<td style=\"width:175px\">Sweden</td>\n\t\t\t<td style=\"width:63px\">2 122</td>\n\t\t\t<td style=\"width:70px\">0.5%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Kuusela <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[18] Kuusela P, Jacobsson BO, Söderlund M, Bejlum C, Almström E, Ladfors L, Hagberg H, Wennerholm U-B :  Transvaginal sonographic evaluation of cervical length in the second trimester of asymptomatic singleton pregnancies, and the risk of preterm delivery.. Acta obstetricia et gynecologica Scandinavica 2015;94(6):598-607\" data-pmid=\"\" data-ref-id=\"191621\" data-url=\"\">[18]</cite></span></td>\n\t\t\t<td colspan=\"1\" rowspan=\"3\" style=\"width:62px\">&lt;30</td>\n\t\t\t<td style=\"width:120px\">16-23</td>\n\t\t\t<td style=\"width:175px\">Sweden</td>\n\t\t\t<td style=\"width:63px\">2 122</td>\n\t\t\t<td style=\"width:70px\">3.4%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">van Os <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[44] van Os MA, van der Ven AJ, Kleinrouweler CE, Schuit E, Kazemier BM, Verhoeven CJ, de Miranda E, van Wassenaer-Leemhuis AG, Sikkema JM, Woiski MD, Bossuyt PM, Pajkrt E, de Groot CJM, Mol BWJ, Haak MC :  Preventing Preterm Birth with Progesterone in Women with a Short Cervical Length from a Low-Risk Population: A Multicenter Double-Blind Placebo-Controlled Randomized Trial.. American journal of perinatology 2015;32(10):993-1000\" data-pmid=\"\" data-ref-id=\"191644\" data-url=\"\">[44]</cite></span></td>\n\t\t\t<td style=\"width:120px\">18-22</td>\n\t\t\t<td style=\"width:175px\">Holland</td>\n\t\t\t<td style=\"width:63px\">20 234</td>\n\t\t\t<td style=\"width:70px\">0.2%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"width:82px\">Grobman <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[45] Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, Tita ATN, Rouse DJ, Sorokin Y, Wapner RJ, Leveno KJ, Blackwell S, Esplin MS, Tolosa JE, Thorp JM, Caritis SN, Van Dorsten JP,  :  17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.. American journal of obstetrics and gynecology 2012;207(5):390.e1-8\" data-pmid=\"\" data-ref-id=\"191646\" data-url=\"\">[45]</cite></span></td>\n\t\t\t<td style=\"width:120px\">16-22</td>\n\t\t\t<td style=\"width:175px\">USA</td>\n\t\t\t<td style=\"width:63px\">15 435</td>\n\t\t\t<td style=\"width:70px\">10%</td>\n\t\t</tr>\n\t</tbody>\n</table>\n<br>\n<strong>When to initiate the progesterone supplementation?</strong><br>\nThe included studies initiated the treatment before gestational week 25 in case of cervix length below 25 mm.&nbsp;<br>\n&nbsp;<br>\n<strong>When to stop the progesterone supplementation?</strong><br>\nThe included studies stopped the treatment between 34 and 37&nbsp;weeks gestation.&nbsp;Some obstetricians might recommend continuation until 37 gestational week, due&nbsp;to Csapo´s progesterone block theory&nbsp;[25],&nbsp;i.e. fear of labour contractions as a result of progesterone withdrawal.",
  "trackRational" : "The majority of studies includes women with a history of preterm birth before week 37. There is only one study including women with a history of preterm birth before week 34, the Norman study <span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[29] Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J :  Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.. Lancet (London, England) 2016;387(10033):2106-16\" data-pmid=\"\" data-ref-id=\"191631\" data-url=\"\">[29]</cite></span>. We find it mainly clinically relevant to prevent preterm birth before week 34 and therefore the Norman study was set as a comparator in the meta-analysis.",
  "trackAdaptation" : "",
  "keyInfo" : {
    "keyInfoType" : "SUMMARY",
    "recommendationId" : 51120,
    "benefits" : "Vaginal administration of progesterone is associated with reversible side effects as outlined in the background section.&nbsp;<br>\n<br>\n<strong>Preterm birth</strong><br>\nVaginal administration of progesteroen in women with a short cervix is associated with a net benefit of reducing the risk of preterm birth (RR 0.63; CI 95%&nbsp;0.48&nbsp;-&nbsp;0.83). &nbsp;<br>\n<br>\n<strong>Long-term (2 years) mortality and morbidity in infants, including cerebral palsy</strong><br>\nWe refer to key info for \"Progesterone for women with history of preterm birth\" in section 3 for elaboration of the possible benefits and harms on the offspring.&nbsp;<br>\n<br>\n<strong>Serious maternal adverse effects, including cancer</strong><br>\nWe refer to key info for \"Progesterone for women with history of preterm birth\" in section 3 for elaboration of this subject as we do not expect any difference in benefits and harms related to indication for treatment (history or short cervix).",
    "trackBenefits" : "Vaginal administration of progesterone is associated with reversible side effects as outlined in the background section.&nbsp;<br>\n<br>\n<strong>Preterm birth</strong><br>\nVaginal administration of progesteroen in women with a short cervix is associated with a net benefit of reducing the risk of preterm birth (RR 0.63; CI 95%&nbsp;0.48&nbsp;-&nbsp;0.83). &nbsp;<br>\n<br>\n<strong>Long-term (2 years) mortality and morbidity in infants, including cerebral palsy</strong><br>\nWe refer to key info for \"Progesterone for women with history of preterm birth\" in section 3 for elaboration of the possible benefits and harms on the offspring.&nbsp;<br>\n<br>\n<strong>Serious maternal adverse effects, including cancer</strong><br>\nWe refer to key info for \"Progesterone for women with history of preterm birth\" in section 3 for elaboration of this subject as we do not expect any difference in benefits and harms related to indication for treatment (history or short cervix).",
    "evidence" : "Overall study quality of the included trials was judged as fair to good. However in som cases sufficiently detailed information for deciding on study quality was not avilable.",
    "trackEvidence" : "Overall study quality of the included trials was judged as fair to good. However in som cases sufficiently detailed information for deciding on study quality was not avilable.",
    "preferences" : "",
    "trackPreferences" : null,
    "resources" : "In this guideline, we did not compare progesterone-treatment with alternatives including vaginal cerclage, abdominal&nbsp;cerclage, and relief from physical activities. However, several studies indicate a positive effect of cerclage for selected&nbsp;cases&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[46] Berghella V, Ciardulli A, Rust OA, To M, Otsuki K, Althuisius S, Nicolaides KH, Roman A, Saccone G :  Cerclage for sonographic short cervix in singleton gestations without prior spontaneous preterm birth: systematic review and meta-analysis of randomized controlled trials using individual patient-level data.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2017;50(5):569-577\" data-pmid=\"\" data-ref-id=\"191648\" data-url=\"\">[46]</cite></span>, especially when the cervix is very short.<br>\nFor further consideration - see section 3, Key info for \"Progesteron for women with history of preterm birth\".",
    "trackResources" : "In this guideline, we did not compare progesterone-treatment with alternatives including vaginal cerclage, abdominal&nbsp;cerclage, and relief from physical activities. However, several studies indicate a positive effect of cerclage for selected&nbsp;cases&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"\" data-label=\"[46] Berghella V, Ciardulli A, Rust OA, To M, Otsuki K, Althuisius S, Nicolaides KH, Roman A, Saccone G :  Cerclage for sonographic short cervix in singleton gestations without prior spontaneous preterm birth: systematic review and meta-analysis of randomized controlled trials using individual patient-level data.. Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2017;50(5):569-577\" data-pmid=\"\" data-ref-id=\"191648\" data-url=\"\">[46]</cite></span>, especially when the cervix is very short.<br>\nFor further consideration - see section 3, Key info for \"Progesteron for women with history of preterm birth\".",
    "benefitsStrength" : "WEAK",
    "evidenceStrength" : "MODERATE",
    "preferencesStrength" : "STRONG",
    "resourcesStrength" : "STRONG",
    "interventions" : [ ],
    "links" : [ ]
  },
  "referenceId" : [ 191631, 191643, 191659, 191642, 191640 ],
  "picoId" : [ 53672 ],
  "links" : [ ]
} ]

  var op = {'success':'','errorMessage':'','result':''};

  if (info.hist_preterm && info.short_cervix == false) {
    op['result'] = rec[0]['text'];
    op['success'] = 1;
    op['errorMessage'] = '-';
  }
  else if (info.hist_preterm == false && info.short_cervix) {
    op['result'] = rec[1]['text'];
    op['success'] = 1;
    op['errorMessage'] = '-';
  }
  // might not need this case?
  else if (info.hist_preterm && info.short_cervix) {
    op['result'] = rec[0]['text'] + rec[1]['text'];
    op['success'] = 1;
    op['errorMessage'] = '-';
  }
  else {
    op['success'] = 0
    op['errorMessage'] = 'No recommendations; No history of preterm birth, nor does the patient have a short cervix';
  }

  return op;

}
